Search

Your search keyword '"Vranic, Ivana"' showing total 127 results

Search Constraints

Start Over You searched for: Author "Vranic, Ivana" Remove constraint Author: "Vranic, Ivana"
127 results on '"Vranic, Ivana"'

Search Results

2. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

6. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure

9. Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

15. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

16. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

19. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

20. Enhanced Publication Content for the manuscript: Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

21. Plain language summary for the manuscript: Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

22. sj-docx-1-tab-10.1177_1759720X221149965 – Supplemental material for Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

24. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

25. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

26. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

30. RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

31. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.

33. Enhanced Publication Content for the manuscript: Risk of major adverse cardiovascular events with tofacitinib vs tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

34. Plain language summary for the manuscript: Risk of major adverse cardiovascular events with tofacitinib vs tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

37. Additional file 2 of Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

41. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

42. Sudden Cardiac Death: Predictors, Prevalence and Clinical Perspectives

44. Visibility of sculpted matter and form : Michelangelo’s Rondanini Pietà and the ontological nature of sculpture

45. EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: 49 WEEK SUMMACTA DATA

46. SUMMACTA: A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Tocilizumab SC versus Tocilizumab IV, in Combination with Traditional DMARDs in Patients with Moderate to Severe RA

47. O22. Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab In Combination with Traditional Dmards in Patients with Rheumatoid Arthritis: 49 Week Summacta Data

Catalog

Books, media, physical & digital resources